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Psoriasis skin area severity
index (PASI);
Modified Sharp-van der
HeijdeAbstract Introduction: Interleukin-34 (IL-34) is a newly discovered cytokine essential for skin
homoeostasis. It is involved in macrophage differentiation, osteoclastogenesis and inflammation.
This could suggest a potential role in the pathogenesis of psoriasis and psoriatic arthritis (PsA).
Aim of the work: To assess serum IL-34 level in psoriatic patients with and without arthritis and
to correlate it with disease activity and severity.
Patients and methods: Serum IL-34 level was measured in 45 psoriasis patients (21 had PsA) and
20 healthy controls. Patients were clinically assessed using psoriasis skin area severity index (PASI),
composite psoriasis disease activity index (CPDAI) and peripheral joint score (PJS). Radiological
assessment of hands and feet was done using modified Sharp-van der Heijde (mSvH) scoring
method for PsA.
Results: The mean age of the PsA patients (47.4 ± 10.2 years) was comparable with the psoriasis
only patients (42.5 ± 7.5 years) and control (43.4 ± 7 years). Serum IL-34 was significantly higher
among PsA patients compared to those without arthritis and controls (median = 2500 ng/L,
512 ng/L and 325 ng/L, respectively). CPDAI was significantly higher in PsA compared to patients
without arthritis. PASI scores were comparable between patients. Serum IL-34 level correlated sig-
nificantly with each of PASI, CPDAI and PJS but not with the mSvH score. Receiver operator
characteristic curve analysis revealed that serum IL-34 testing showed excellent diagnostic perfor-
mance for PsA in psoriasis patients.100.
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Egyptian Rheumatologist (2016), http://dx.dConclusion: The markedly elevated IL-34 serum level in PsA patients compared to non-arthritic
ones and its remarkable correlation with PsA disease activity, suggest its importance as a marker for
arthritis in psoriasis patients.
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Psoriasis is a common immune-mediated skin disease [1]. Pso-
riatic arthritis (PsA) is a chronic inflammatory arthritis that
develops in at least 0.1–1% of the general population [2] and
5.8–30% of patients with psoriasis [3]. The diagnosis of PsA
in psoriatic patients can be missed because most of the patients
present with symptoms other than frank arthritis [4]. Inflam-
matory cytokines play an essential role in the immune-
pathogenesis of psoriasis and PsA [5].
Psoriatic arthritis is characterized by extensive bone resorp-
tion. Myeloid derived cells differentiate into osteoclasts in the
presence of macrophage colony stimulating factor (MCSF)
and receptor activator nuclear kappa beta ligand (RANKL).
RANK and colony stimulating factor 1 receptor (c-Fms) are
expressed on osteoclast precursors in inflamed synovium and
subchondral bone and upon stimulation with MCSF and
RANKL develop into mature bone resorbing cells [6,7].
Interleukin-34 (IL-34) is a newly discovered cytokine pro-
duced by keratinocytes in the epidermis and by neurons in
the brain. It has a non-redundant function in skin homoeosta-
sis [8]. It shares a common receptor (c-Fms) with MCSF [9].
Although, they shared this common receptor on monocytes,
their signal transduction mechanism and biological activity
were found to be non-identical [10]. An overlap, however, in
the function of IL-34 and MCSF in bone proved IL-34 is
important for osteoclastogenesis and macrophage differentia-
tion [11]. It has been shown that IL-34 could substitute MCSF
entirely for its RANKL-induced osteoclastogenesis [12]. Injec-
tion of IL-34 into mice increased the number of osteoclast pre-
cursors and enhanced bone resorption [13]. The inflammatory
role of IL-34 is elaborated in monocyte activation and in the
up-modulation of chemokines [14,15]. Pro-inflammatory
cytokines such as tumour necrosis factor alpha (TNFa) and
interleukin-1 beta (IL-1b) can stimulate IL-34 expression [16]
whereas IL-34 can increase the production of interleukin-17
(IL-17) [17,18]. TNFa and IL-17 are both involved in patho-
genesis of psoriasis and inflammatory arthritis like rheumatoid
arthritis (RA) and PsA [19,20]. Antibodies against the receptor
that block binding of IL-34 and MCSF-1 to (c-Fms) receptors
on macrophages has been shown to downregulate peripheral
blood monocyte implicated in inflammatory arthritis [21].
Also, it completely blocked osteoclastogenesis and bone ero-
sions induced by TNFa injection or inflammatory arthritis
[22].
It was previously observed that MCSF in synovial fluid of
PsA patients was not elevated to the same extent as in RA [23]
even though the inflamed synovium in PsA resembles that of
RA [24]. Previous work in RA patients revealed, RA derived
fibroblast like synoviocytes and osteoblasts were found to pro-
duce IL-34 in response to TNFa [14,25]. This could make us
hypothesize that IL-34 may replace MCSF and contribute to
pathogenesis of PsA. In this work we aimed to assess serumet al. Evaluation of IL-34 in psoriasis a
oi.org/10.1016/j.ejr.2016.05.008IL-34 level as a possible biomarker in psoriasis with or without
PsA and to correlate its level with clinical disease activity and
severity.
2. Patients and methods
This cross-sectional study included 45 patients diagnosed with
psoriasis vulgaris, 21 of whom also had PsA. Patients were
randomly recruited from outpatient clinics of Dermatology,
Photo-therapy and Physical Medicine and Rheumatology at
Ain Shams University Hospital. The control group consisted
of 20 healthy age and sex matched volunteers with no history
of joint problem and no family history of psoriasis. Both
patients and controls had no history suggestive of diabetes,
infection, cancer or other chronic inflammatory disease.
Patients on steroids, disease modifying drugs or biological
therapy for at least the last 6 months were excluded from the
study. The study was conducted in accordance with the World
Medical Association Declaration of Helsinki for human sub-
jects and approved by the ethics committee of the Faculty of
Medicine Ain Shams University, and all participants gave us
their written informed consent.
Patients were subjected to full history taking and thorough
clinical examination including skin, hair, mucous membrane
and joint examination. The diagnosis of Psoriasis was made
clinically based on characteristic lesions. PsA patients fulfilled
the diagnostic criteria defined according to the Classification
Criteria for Psoriatic Arthritis (CASPAR) [4].
Functional assessment of the patients was performed
according to the
Dermatology life quality index (DLQI): It is a 10-item ques-
tionnaire used to assess the effect of a dermatologic condition
on a patient’s quality of life (QoL) over the last week. Each
question scores 0–3 (total possible score of 0–30). Higher
scores present a greater effect on QoL [26].
Modified health assessment questionnaire (MHAQ): con-
tains 20 items divided into 8 domains; dressing, grooming, aris-
ing, eating, walking, hygiene, reach, grip and common daily
activities. Each item has a score range of 0 (no difficulty) to
3 (unable to do). The highest scores are summed (0–24) and
divided by the number of scored domains to yield a score from
0 to 3 [27].
Psoriasis area and severity index (PASI): was measured for
all patients: the PASI measures both surface area and lesional
severity of psoriasis. Four items are measured (surface area,
severity of erythema [redness], induration [thickness], and
desquamation [scale]) evaluated for 4 body areas (head, trunk
and upper and lower extremities) assessed separately and then
combined using weighting based on the surface area repre-
sented by each area (head = 0.1, upper extremities = 0.2,
trunk = 0.3, and lower extremities = 0.4). The degree of ery-
thema, induration, and scale in each area is judged on a 0–4
scale, the sum of which represents disease severity. The areand psoriatic arthritis patients: Correlation with disease activity and severity, The
Figure 1 Comparison between serum interleukin-34 level in
psoriasis patients with and without arthritis and normal controls.
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on the estimated percentage of lesional area (0 = 0%,
1 = 10%, 2 = 10–29%, 3 = 30–49%, 4 = 50–69%, 5 = 70–
89%, and 6 = 90–100%). Body scores are multiplied by the
disease severity score and the weighting for each body area,
yielding a score between 0 and 72 [28].
Peripheral joint score (PJS): was used to assess peripheral
joints with one point for each joint involved (range 0–70). Joint
involvement was defined as synovial swelling and/or joint
deformity not solely attributed to osteoarthritis [29].
Disease activity was assessed using the composite psoriatic
disease activity index (CPDAI). Disease involvement was
assessed in up to five domains: peripheral joints, skin, enthesi-
tis, dactylitis and spinal manifestations. Domains were scored
from 0 (uninvolved) to 3 (severe). Peripheral joint score
depends on number of joints involved and the presence or
absence of impaired function using the health assessment ques-
tionnaire (in our work MHAQ score <0.3 was considered nor-
mal function). Skin disease score depends on (PASI) and
(DLQI). Enthesitis and dactylitis were scored according to
the number of involved sites/fingers and the presence or
absence of impaired function. Spinal manifestations were
scored using Bath ankylosing spondylitis activity index (BAS-
DAI) [30] and presence or absence of impaired function. Indi-
vidual domain scores were summed giving an overall
composite score (range 0–15) [31].
Serum IL-34 level was assessed using quantitative ELISA
(enzyme linked immuno-sorbent assay) by (WH-1752, Wkea
Med Supplies Corp, Changchun, Jilin, China). 2 ml of venous
blood was collected and kept at 70 C until analysed. This
assay employs sandwich enzyme immunoassay technique. A
monoclonal antibody specific for IL-34 has been pre-coated
onto a micro plate. Standards and samples are pipetted into
the wells and any IL-34 present is bound by the immobilized
antibody. After washing away any unbound substances, an
enzyme-linked polyclonal antibody specific for Il-34 is added
to the wells. Following a wash to remove any unbound
antibody-enzyme reagent, a substrate solution is added to
the wells and colour develops in proportion to the amount
of IL-34 bound in the initial step. The colour development is
stopped and the intensity of the colour is measured.
C-reactive protein (CRP) was measured using latex in
patients and controls.
Radiological examination in the patients included:
Plain X-ray: postero-anterior view of the hands and feet
were obtained for PsA patients. Radiographs were scored for
erosions and joint space narrowing (JSN) according to modi-
fied Sharp-van der Heijde (mSvH) scoring method for PsA
[32]. The maximum score for erosions was 200 for hands and
120 for feet (max. erosions 320). The maximum score for
JSN was 160 for hands and 48 for feet (max. JSN 208). Max-
imum possible total score is 528.
Dual energy X-ray absorptiometry (DEXA): bone mineral
density (BMD) was measured for PsA patients only (as part
of their routine workup available at time of study). Instrument
used for scans was GE Medical Systems, Lunar (DPX-MD+)
at femoral neck and lumbar spine (L1–L4) in anterior and pos-
terior projections. By DEXA, results were recorded for each
patient as T-scores (difference in SD from the mean of a
healthy young adult) and Z-scores (difference in SD from the
mean of patients same age and sex). Osteoporosis and osteope-Please cite this article in press as: Farrag DA et al. Evaluation of IL-34 in psoriasis an
Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.008nia (low bone mass) were defined as T-scores less than 2.5
and T-score between 1 and 2.5 respectively [33].
Statistical analysis: data were coded, tabulated, and statisti-
cally analysed using IBM SPSS statistics software version 22.0,
IBM Corp., Chicago, USA, 2013. Quantitative data were pre-
sented as mean ± SD and range (minimum–maximum) for
parametric and as median and 1st–3rd inter-quartile range
for non-parametric variables while qualitative data were pre-
sented as number and percentage. Comparison of two para-
metric quantitative variables was done using independent t-
test and by Mann–Whitney U between non-parametric data.
Qualitative data were compared using Chi square test for dif-
ferences between proportions. Comparison of more than 2
groups was done by analysis of variance (ANOVA). Correla-
tions were done using Spearman rho test for numerical non
parametric data. Receiver operator characteristic (ROC) curve
was used to evaluate the performance of serum IL-34 to differ-
entiate PsA patients from those with psoriasis only and sensi-
tivity, specificity, positive likelihood ratio (LR), negative LR
and diagnostic accuracy of different cut off points were calcu-
lated. P value <0.05 was considered significant.
3. Results
The study included 45 patients with psoriasis vulgaris with a
mean age of 44.8 ± 9.1 (range: 30.0–63.0) and were 25 males
and 20 females; 21 (46.7%) had PsA (group-A) and 24
(53.3%) had psoriasis without arthritis (group-B). 20 age
(43.4 ± 7 years; 32–58 years) and gender (7 males and 13
females) matched healthy individuals volunteered as controls.
Serum IL-34 was significantly higher among PsA patients
(median = 2500 ng/L) compared to patients without arthritis
(median = 512 ng/L) and controls (median = 325 ng/L;
range: 300–525 ng/L) (p< 0.001); while the difference between
those without arthritis and control did not reach significance
(Fig. 1). The CRP was negative in the 20 controls. The demo-
graphic features, clinical characteristics, functional status and
disease activity as well as the serum IL-34 and CRP levels in
the psoriatic patients with and without arthritis are presented
in Table 1. CPDAI was significantly higher in PsA patientsd psoriatic arthritis patients: Correlation with disease activity and severity, The
Table 1 Demographic features, clinical characteristics, functional status and disease activity as well as the serum IL-34 and CRP
levels in the psoriatic patients with and without arthritis.
Variables PsA (N= 21) Psoriasis only (N= 24) P
Age (years) 47.4 ± 10.2 (34–63) 42.5 ± 7.5 (30–60) 0.08
Gender M:F 11:10 (52.4%:47.6%) 14:10 (58.3%:41.7%) 0.69
Ps duration (years) 10 (4.5–22.5) 4.5 (2–11.3) 0.008
PASI 10.9 (9.1–22.4) 10 (4.2–14.7) 0.23
Nail involvement 14 (66.7%) 2 (8.3%) <0.001
MHAQ 1 (0.6–1.4) 0.5 (0–1) 0.013
DLQI 13 (9–25) 0 (0–11) 0.002
CPDAI 10 (6.5–11) 1.5 (1–2) <0.001
IL-34 (ng/L) 2500 (1100–2525) 512.5 (300–1000) <0.001
+ve CRP 8 (38.1%) 6 (25%) 0.34
Results are presented as mean ± SD, median (inter-quartile range) or n (%). Ps, psoriasis; PASI, psoriasis skin area severity index; MHAQ,
modified health assessment questionnaire; DLQI, dermatology life quality index; CPDAI, composite psoriasis disease activity index; IL-34,
interleukin-34; CRP, C-reactive protein. Bold values are significant at p< 0.05.
Table 2 Interleukin-34 level in different grades of bone mineral density in psoriatic arthritis patients.
BMD in PsA patients (n= 21) P
Normal (n= 7) Osteopenia (n= 6) Osteoporosis (n= 8)
IL-34 level (ng/L) 1750 (1000–2500) 1200 (1000–1875) 2550 (2500–2550) <0.001
Z-score Lumbar 0.7 (0.9 to 0.4) 1.6 (2.0 to 0.4) 2.8 (2.9 to 2.7) <0.001
Hip 0.3 (0.5 to 0.1) 1.2 (1.7 to 0.1) 2.1 (2.2 to 2.0) <0.001
Results are expressed as median (inter-quartile range). BMD. bone mineral density; PsA: psoriatic arthritis; IL-34: interleukin-34. Bold values
are significant at p< 0.05.
Table 3 Correlation between serum IL-34 and some clinical and radiological findings in psoriatic patients with and without arthritis.
Serum IL-34 (ng/L)
Variables r (p) PsA (N= 21) Psoriasis only (N= 24)
Ps duration 0.23 (0.25) 0.25 (0.24)
PASI 0.92 (<0.001) 0.74 (<0.001)
MHAQ 0.91 (<0.001) 0.71 (<0.001)
DLQI 0.65 (<0.001) 0.75 (<0.001)
Arthritis duration 0.62 (0.003) NA NA
Dactylitis 0.82 (<0.001) NA NA
Enthesitis 0.01 (0.95) NA NA
PJS 0.63 (0.002) NA NA
BASDAI 0.84 (<0.001) NA NA
CPDAI 0.78 (<0.001) 0.63 (<0.001)
mSvH score 0.28 (0.22) NA NA
DXA Lumbar spine 0.5 (0.02) NA NA
Hip joint 0.56 (0.008) NA NA
Ps, psoriasis; PASI, psoriasis skin area severity index; MHAQ, modified health assessment questionnaire; DLQI, dermatology life quality index;
PJS, peripheral joint score, dactylitis, enthesitis; BASDAI, bath ankylosing spondylitis disease activity index; CPDAI, composite psoriasis
disease activity index; mSvH, modified Sharp van der Heijde score; DXA, dual energy X-ray absorptiometry; Bold values are significant at
p< 0.05.
4 D.A. Farrag et al.compared to those without arthritis. PsA patients presented
with arthritis of 0.5–10 years duration. Fourteen (67%) of
them presented with poly-arthritis and 8 of which had con-
comitant axial spine affection. Seven of the patients (33%) pre-
sented with pauci-articular arthritis and 4 of them had
concomitant spine affection. Dactylitis was present in 10 and
enthesitis was detected in 14 of the patients. Bone densitometryPlease cite this article in press as: Farrag DA et al. Evaluation of IL-34 in psoriasis a
Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.008of lumbar spine and hip regions revealed that 38% of PsA
patients were osteoporotic and 28.5% had osteopenia and
33.3% had normal BMD. Mean Z-scores of PsA patients with
different degrees of bone densities and their mean IL-34 serum
levels are shown in Table 2. IL-34 was significantly higher
among PsA osteoporotic patients compared to those with
osteopenia and normal bone density.nd psoriatic arthritis patients: Correlation with disease activity and severity, The
Figure 2 Correlation between serum interleukin-34 level and
composite psoriasis disease activity index (CPDAI) among psori-
atic arthritis patients.
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ical and radiological findings in psoriatic patients with and
without arthritis are shown in Table 3. Correlation between
IL-34 and CPDAI among PsA patients is shown in Fig. 2.
The diagnostic performance of serum IL-34 level to differ-
entiate patients with and without arthritis using ROC curve
analysis revealed that it was excellent with a high sensitivity
and specificity and an area under curve (0.901) (Fig. 3). Serum
IL-34 level cut off value atP1750 ng/L showed a specificity of
100% (95% CI 87–100%), sensitivity of 66.7% (95% CI 51.8–
66.7%), positive LR 10 (4–10), negative LR 0.3 (0.3–0.6) and a
diagnostic accuracy of 84.4% (70.6–84.4%). Serum IL-34 level
cut off value at P1000 ng/L showed a specificity of 54.2%
(95% CI 41–54.2%), sensitivity of 100% (95% CI 85–100%),
positive LR 2.2 (1.4–2.2), negative LR 0 (0–0.4) and a diagnos-
tic accuracy of 75.6% (61.5–75.6%).Figure 3 Receiver operator characteristic (ROC) curve showing the
patients with and without arthritis and the suggested cut off values. (
curve (AUC) = (0.901) at 95% CI = (0.82–0.99) (p< 0.001). (2) Grou
valueP1000 ng/L, the sensitivity and specificity were 100% (95% CI:
off values P1750 ng/L were 66.7% (51.8–66.7%) and 100% (87–100%
Please cite this article in press as: Farrag DA et al. Evaluation of IL-34 in psoriasis an
Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.0084. Discussion
Interleukin-34 is a cytokine essential for skin homoeostasis [8].
It is involved in macrophage differentiation, osteoclastogenesis
and inflammation [11,14–17]. In our study serum IL-34 level
was significantly higher among PsA patients compared to
those without arthritis and normal controls. This is in accor-
dance with previous work on inflammatory arthritis like RA
and ankylosing spondylitis where IL-34 was elevated in serum
of patients [18,34]. The CRP value was significantly higher in
patients compared to controls. In the work of Tian et al. [18]
on RA patients, a significant positive correlation was found
between IL-34 levels and inflammation variables including
CRP.
In the present work, duration of psoriasis as well as nail
involvement was significantly higher in PsA compared to
patients without arthritis. Skin lesions usually precede articu-
lar symptoms in more than 75–80% of patients with PsA
[35]. Also, nail changes are observed in about 40% of psoriasis
patients, and this percentage increases to about 80% in PsA
[36]. The PASI was not significantly different between PsA
and psoriasis only patients. However, functional capacity
indices measured in our patients using MHAQ and DLQI were
significantly higher among PsA compared to psoriasis only
patients. PASI measures disease severity at the time of assess-
ment and does not provide any information about the patient’s
psychological and mental well-being. In fact, two patients with
similar PASI score, may be affected quite differently by their
disease [37,38] and attributed to cumulative effect of skin
and joint involvement, QoL and functioning may be further
impaired in patients with PsA.
In this study composite psoriasis disease activity index
(CPDAI) was significantly higher in PsA patients compared
to those without arthritis. This could be also attributed to
involvement of skin as well as joints and enthesis in PsA [39].
A significant correlation was also detected in this work
between serum IL-34 level and PASI score, functional indicesefficacy of serum IL-34 level in differentiation between psoriatic
1) ROC curve showed high sensitivity and specificity. Area under
p A = psoriatic arthritis, Group B = psoriasis only. At the cut off
85–100%) and 54.2% (95% CI: 41–54.2%) respectively. At the cut
) respectively.
d psoriatic arthritis patients: Correlation with disease activity and severity, The
6 D.A. Farrag et al.and CPDAI in both groups of patients. Also in PsA group, a
significant correlation was detected between serum IL-34 and
each of BASDAI, PJS and dactylitis score. This signifies its
association with psoriatic disease activity especially arthritis.
A significant relation was found between IL-34 levels in RA
patients and disease activity [18].
Regarding severity of arthritis, in our work no significant
correlation was detected between IL-34 serum level and radio-
graphic joint damage scores in the hands and feet calculated
using the mSvH score in PsA patients. This could be attributed
to long duration of un-treated arthritis and the different clini-
cal presentations of arthritis in our patients which didn’t give
us a better chance for comparison of patients with and without
erosions. Moreover, no follow up for radiographic progression
was done in our work. Previous work of Moon et al. [17] in RA
patients revealed no relation between serum IL-34 level and
radiological joint damage scores. However, another study
revealed a significant correlation with radiographic progres-
sion using mSvH score [40].
In this study BMD was measured in PsA patients knowing
it’s a limitation of the study but previous work in psoriasis and
PsA patients revealed they did not present with low BMD
compared to controls [41]. However Attia et al. in their work
demonstrated significant lower bone density in PsA patients
compared to those without arthritis and normal controls,
and the risk of osteoporosis in PsA patients increased with
the increase in number of arthritic joints [42]. Significant neg-
ative correlation was detected between IL-34 serum level in
PsA patients and Z-score of lumbar spine and hip joint. Previ-
ous work in vitro showed that IL-34 could promote osteoclas-
togenesis and bone resorption [13,43]. In our study IL-34 mean
serum level was highest among PsA patients with osteoporosis.
Previous work on RA patients revealed a significant correla-
tion between serum IL-34 levels and degree of osteoporosis
[40]. However, Moon et al. in their work found no relation
between serum IL-34 level and systemic osteoporosis [17].
The present work revealed a correlation between serum IL-
34 level and systemic bone loss but not radiographic damage
scores in PsA patients. Dalbeth et al. [44] revealed that MCSF
(cytokine which shares receptor with IL-34) correlated with
radiographic damage scores but not with total hip BMD in
PsA patients [44]. These findings suggest further studies could
emphasize the role of each IL-34 and MCSF in bone resorp-
tion in PsA.
In this study ROC curve analysis revealed; increased sensi-
tivity and specificity of serum IL-34 as a marker for arthritis in
psoriasis patients. The cut-off value of (IL-34P 1750 ng/L)
was highly specific for confirming PsA in psoriasis patients.
The cut off value of (IL-34P 1000 ng/L) was more sensitive
for early detection of positive arthritic cases. We suggest fur-
ther evaluation of serum IL-34 as a diagnostic and screening
marker for suspected PsA in a larger number of psoriasis
patients. It would help with early detection and management
of arthritis.
In conclusion; serum IL-34 could be a new marker for PsA
disease activity. Serum IL-34 was significantly higher in PsA
patients compared to those without arthritis and normal con-
trols. Serum IL-34 showed a significant correlation with PASI,
CPDAI and systemic bone loss but showed no relation to radi-
ological joint damage scores in PsA.Please cite this article in press as: Farrag DA et al. Evaluation of IL-34 in psoriasis a
Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.008Conflict of interest
None.
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